Background: Though de novo mitral regurgitation (MR) is frequently seen in patients who have undergone coronary artery bypass surgery (CABG), its incidence, predictors, and mechanisms are not known. Methods: Our surgical registry was screened for patients undergoing isolated CABG who had preoperative and postoperative resting echocardiograms performed at our institution with 2+ MR preoperatively. This yielded 438 patients. Progression to 3-4+ MR post-CABG was correlated with clinical, electrocardiographic, echocardiographic, and operative variables. Results: New 3-4+ MR developed in 11 (10%) of the 108 patients with no prior MR, 21 of the 180 (12%) patients with pre-CABG 1+ MR, and 37 of the 150 (25%) patients with pre-CABG 2+ MR. MR progression correlated with female gender (42% vs 27%, p = 0.01), history of renal insufficiency (12% vs 5%, p = 0.05), prior-CABG (30% vs 17%, p = 0.01), lack of beta-blocker use (19% vs 35%, p = 0.008), lower incidence of significant PDA stenosis grafted (88% vs 98%, p = 0.003), lower preoperative LVEF (42 AE 19% vs 50 AE 17%, p = 0.001), larger LV size ( p = 0.01), pre-CABG MR grade ( p = 0.0002), and pre-CABG presence of LBBB block (20% vs 4%, p < 0.0001). Independent predictors of MR progression, pre-CABG, were female gender ( p = 0.002), history of renal insufficiency ( p = 0.05), lack of beta-blocker use ( p = 0.006), MR grade ( p = 0.02), and presence of LBBB ( p = 0.005). Conclusion: Development of significant MR following isolated CABG is common and may be related to incomplete myocardium revascularization, especially in the PDA area and LV remodeling. Preoperative, beta-blocker use may be protective against its development. #
Introduction
Mitral regurgitation (MR) is common in patients with coronary artery disease and those undergoing coronary artery bypass surgery (CABG) [1, 2] . Behavior of significant MR grades and its response to CABG, has been studied and has been shown to regress with a reduction in left ventricular (LV) size [3] . Ischemic MR depends upon LV size and geometry, which may potentially progress in a patient with coronary artery disease even after CABG. However, the natural history of milder degrees of MR following CABG is not known despite the potential impact on prognosis. We investigated the clinical, electrocardiographic, echocardiographic, and surgical variables associated with the progression of mild degrees of MR following isolated CABG.
Methods

Study population
This retrospective observational cohort study was conducted at a tertiary medical center. Prospectively collected comprehensive computerized surgical registry was screened for adult patients who underwent CABG from July 1993 to December 2001 and had both preoperative and postoperative echocardiograms at our institution. Of the 523 patients meeting these criteria, 438 patients had 0-2+ MR (0+ MR in 108, 1+ MR in 180, and 2+ MR in 150) on a 0-4 scale on the preoperative echocardiograms. Echocardiograms were performed with a mean of 99 AE 304 days before and 597 AE 645 days after CABG. Pre-EKGs were obtained with a mean of 63 AE 294 days before and 265 AE 446 days after CABG.
Clinical data
The following patient characteristics were collected: (1) patient demographics: age and gender; (2) non-cardiac co-morbidities: presence of diabetes mellitus, renal insufficiency (serum creatinine >2 mg/dl), renal replacement therapy with dialysis, CVA, COPD or peripheral vascular disease; (3) cardiac co-morbidities: extent of coronary artery disease (history of left-main disease and the number of diseased coronary vessels), history of myocardial infraction, congestive heart failure, cardiogenic shock and arrthymia; (4) prior cardiac surgical history: history of prior CABG; (5) surgical variables: perfusion time, cross-clamp time, number, type and location of grafts and use of intra-aortic balloon pump; and (6) medication use prior to surgery: use betablockers, ACE-inhibitor, digoxin, and diurectics.
Echocardiographic data
Trans-thoracic or trans-esophageal echocardiographic examinations were performed with the use of standard techniques and commercially available equipment and anatomic measurements were made according to the American Society of Echocardiography guidelines [4] . The following parameters were collected on pre-CABG and post-CABG echocardiograms: (1) LVEF, (2) LV dimensions and wall thickness, (3) relative wall thickness calculated combined wall thickness/LVd, (4) MR grade as follows: 0 = none, 1 = mild, 2 = moderate, 3 = moderate to severe, 4 = severe based on jet size, size of vena contracta and area of flow acceleration and systolic flow reversal in the pulmonary veins, and (5) wall motion abnormalities: hypokinesis, dyskinesis or akinesis in the anterior wall and non-anterior wall (posterior and inferior) walls with or without preserved wall thickness.
Electrocardiographic data
EKG data were collected from the MUSE system (digitally stored EKG database). Following parameters were collected on all EKGs: (1) rhythm: sinus rhythm, atrial fibrillation (AF) or paced, (2) right and left bundle branch blocks (RBBB, LBBB), and (3) pathological Q-waves in: anterior wall and non-anterior distributions.
Surgical data
This was an observational study; hence, choice of number of grafts, and cardioplegic technique, were made entirely by the operating surgeon. None had mitral valve or any other valvular surgery.
Statistical analysis
Pre-CABG and post-CABG clinical, echocardiographic, and EKG variables associated with progression to 3 or 4+ MR (progressors) were identified. Statview 5.01 (SAS Institute Inc., Cary, NC, USA) program was used to assist in the statistical analysis. Groups with and without MR progression were compared using the unpaired t-test or chi-square test. Multivariate logistic regression was used to identify independent predictors of MR progression. The p-value 0.05 was considered to be statistically significant.
Results
Baseline characteristics of the study group
This study group of 438 patients had a mean age of 66 AE 11 years with predominance of male gender (70%) and Caucasian race (82%). The mean LVEF was 49 AE 17%. History of prior CABG was present in 83 (19%) patients. Atrial fibrillation was present in 61 (14%) patients. The mean NYHA class was 3.3 AE 0.8 and CCS class was 3.4 AE 0.7. Pre-CABG, there was no MR in 108 patients (25%), 1+ MR in 180 (41%) patients, and 2+ MR in 150 (34%) patients. Fig. 1) Post-CABG, the mean MR grade increased from 1.1 AE 0.8 to 1.4 AE 1. In patients without pre-CABG MR (n = 108), de novo 3-4+ MR developed in 11 (10%) patients after CABG (3+ in 8 and 4+ in 3). Patients with 1+ MR pre-CABG (n = 180) progressed to 3-4+ MR post-CABG in 21 (12%) patients (3+ in 17 and 4+ in 4). In patients with 2+ MR pre-CABG (n = 150), 3-4+ MR developed in 37 (25%) patients (3+ in 25 and 4+ in 12). In total, de novo 3+ MR developed in 50 (11%) and 4+ MR in 19 (4%) patients post-CABG. Of the 69 patients with 3-4+ MR, in 17 patients (25%), the 3-4+ MR was diagnosed within the first 6 months of CABG. (Table 1) 3.3.
Pattern of MR progression (
Variables associated with MR progression
Clinical variables
Patients with MR progression (n = 69) had predominance of female gender (42% vs 27%, p = 0.01), history of renal insufficiency (12% vs 5%, p = 0.05) and prior-CABG (30% vs 17%, p = 0.01). There was no statistical significant difference in age, history of diabetes mellitus, cardiogenic shock, myocardial infarction, prevalence of left main disease, and average number of diseased coronary vessels.
Medications related to MR progression
Patients with MR progression had a lower use of betablockers (19% vs 35%, p = 0.008). There was a non-significant trend towards higher use of ace-inhibitor (35% vs 25%, p = ns) and ASA (55% vs 53%, p = ns).
Operative variables
In the study population, the mean number of bypass vessels grafted was 3.1 AE 1. In the groups with and without MR progression, there was no difference in the distribution of coronary artery disease, number of vessels grafted, whether arterial or venous grafts were used. However, those with MR progression had a significantly lower incidence of having a significantly stenosed posterior descending artery (PDA) being grafted (88% vs 98%, p = 0.003).
Preoperative echocardiographic variables
Patients with 0-2+ MR progression on pre-CABG echocardiogram had lower mean LVEF (42 AE 19% vs 50 AE 17%, p = 0.001), and a larger left ventricle dimension [LVd (54 AE 9 mm vs 51 AE 8 mm, p = 0.01), LVs (39 AE 12 mm vs 36 AE 11 mm, p = 0.03)]. Progressors also had a higher prevalence of pre-CABG 2+ MR compared to the nonprogressors (54% vs 31%, p = 0.0002).
Changes in echocardiographic variables post-CABG
Post-CABG echocardiogram was done with a mean duration of follow-up of 1.6 years. The mean MR grade increased from 1.1 AE 0.8 to 1.4 AE 1. Progression of MR was associated with reduction in left ventricle ejection function (negative 4 AE 17% vs +1.9 AE 13%, p = 0.002), and increase in left ventricle size [LVd (2 AE 7 mm vs negative 1 AE 6 mm, p = 0.004), and LVs (4 AE 8 mm vs 2 AE 8 mm, p = 0.002)]. Post-CABG, development of new wall motion abnormality in anterior wall was not different in the two groups, yet, development of a new wall motion abnormality in the non-anterior wall motion with preserved myocardium thickness was associated with MR progression (28% vs 16%, p = 0.02).
Perioperative variables
Of the total patients with pre-CABG and post-CABG echocardiograms, only 34 patients that had echocardiogram day of surgery and 45 patients had echocardiogram within a week post-CABG. Only six of these patients had both an echocardiogram day of surgery and an echo within a week post-CABG. Only one of these six had MR progression from 1+ to 4+ MR. Because of the limited number of patients with perioperative echocardiograms, we could not study the risk factors that may contribute to MR progression due to perioperative factors.
Electrocardiographic variables
Pre-CABG EKGs were available in 382 patients and post-CABG EKGs in 338 patients. On the pre-CABG EKG, there was no association between prevalence of sinus rythum, atrial fibrillation, and paced rythum in patients with MR progression. Patients with MR progression had no difference in the prevalence of RBBB, but had a significant higher presence of LBBB (20% vs 4%, p < 0.0001). Pre-CABG, presence of pathological Q-waves in anterior and non-anterior leads was not associated with MR progression. On the post-CABG EKG, MR progression correlated with lack of development of new Q waves in the non-anterior walls (2% vs 17%, p = 0.01) but not in the anterior wall (13% vs 14%, p = ns).
Independent predictors of post-CABG 0-2 AE MR progression
In multivariate logistic regression analysis, pre-CABG variables significant on univariate analysis were entered into the model: female gender, history of renal insufficiency, history of CABG, use of beta-blocker, LVEF, LVd, MR grade, and presence of LBBB. The independent pre-CABG predictors of post-CABG MR progression were as follows: female gender ( p = 0.002, RR = 3.3), history of renal insufficiency ( p = 0.05, RR = 3.8), lack of use of beta-blocker ( p = 0.006, RR = 0.29), MR grade ( p = 0.02, RR = 1.9), and presence of LBBB ( p = 0.005, RR = 5.9). Pre-CABG, history of CABG, LVEF and LV size were not independent predictors of MR progression in the multivariate analysis. The PDA stenosis grafted variable was not used in the analysis as it was a small subset of the entire population.
Subgroup analysis of patients with CABG 2 AE MR
Patients with pre-CABG abnormal mitral valve function and 2+ MR (n = 150) had mean age of 68 AE 10 years, mean LVEF 42 AE 17%, predominance of male gender 84 (56%). Mean MR decreased from 2 to 1.7 AE 1.1 post-CABG. MR progression to 3-4 + MR developed in 37 (25%) patients (3+ in 25 and 4+ in 12). The pre-CABG variables associated with 2+ MR progression were lack of beta-blocker use (19% vs 40%, p = 0.02), greater use of ace-inhibitor (perhaps due to heart failure symptoms) (43% vs 26%, p = 0.04), higher prevalence of LBBB (19% vs 3%, p = 0.001), and significant PDA stenosis not being grafted (93% vs 100%, p = 0.05).
Discussion
Frequency of MR progression
Progression of milder degrees of preoperative MR that can occur post-CABG has not been studied in a systematic fashion. Our study is unique in this regard. We have shown that MR progression or development of 3 or 4+ MR, de novo, after CABG is not uncommon. In our patients, MR progression was seen in 69 (16%) of all patients undergoing CABG. In patients with 2+ MR (n = 150) pre-CABG, progression to 3-4+ MR post-CABG was seen in 37 (25%) patients.
Predictors of MR progression
Predictors of MR progression post-CABG correlated with having poor targets. Patients with smaller coronary arteries like women, patients that have diffuse vascular disease, like patients with renal disease and patients with patchy areas of ischemia like those with prior-CABG, are associated with MR progression. MR progression correlated with the presence of pre-CABG LV dysfunction and large LV size. Although, there was no correlation between MR progression and the extent of coronary artery disease (incidence of left main disease, mean number of diseased vessels), or the mean number of arterial or vein grafts used, having incomplete revascularization in the PDA territory correlated with the progression of MR. The highest rate of MR progression was seen in patients with pre-existing abnormal mitral valve function with 2+ MR pre-CABG ( p = 0.0002). These patients may require very little additional insult for further deterioration of their MR. Beta-blockers were protective, possibly through preoperative or perioperative protection against ischemia and possibly through prevention of LV remodeling which would increase functional MR. Presence of inter-ventricular asynchrony with LBBB presence was also correlated with MR progression.
Mechanistic insights of MR progression
Pathogenesis of MR in patients undergoing CABG is multifactorial. In patients with CAD, functional MR has been related to 3D change in the geometry and distance between the papillary muscle and mitral apparatus [2, 3, 5, 6] . Our data suggest that an increase in LV size is central to MR progression in patients undergoing CABG. This may occur due to inadequate revascularization, especially in the PDA area or natural progression of LV remodeling. This may be facilitated by LBBB and seems to be inhibited by use of beta-blockers. Recently, we have shown that post-CABG 3-4+ MR regression may depend upon adequate revascularization of hibernating myocardium to increase in LV function and decrease LV size [3] . Regional wall motion abnormality in the inferiorposterior LV wall due to development of new ischemia without infract, may additionally, progress MR post-CABG due to change in regional LV geometry.
Presence of pre-existing abnormal mitral valve function with 2+ MR had the highest rate of MR progression. This may probably be due to the fact that an abnormal mitral coaptation mechanism in these patients needed very little additional disturbance to cause worsening of the mitral valve function. Beta-blocker use provided protection presumably through both reduction of ischemia and inhibition of LV remodeling. Use of beta-blocker such as carvedilol has been shown to reduce MR due to prevention or reversal of LV dilation [7, 8] .
The association between LBBB and MR progression is fascinating. This may be due to either faster worsening of LV function with LBBB or intra-ventricular asynchrony caused by LBBB. Cardiac resynchronization therapy (CRT) has been shown to decrease functional MR [9] [10] [11] . In patients with LBBB and low LVEF, MR decreases with LVEF improvement and decrease in the mitral annulus diameter with CRT [10] . Also, MR may improve immediately after CRT therapy due to improved inter-papillary muscle distance and coordinated LV function [11] . A decrease in effective regurgitant orifice area and regurgitant volume by as much as 40% was seen with CRT presumably due to an increase in trans-mitral closing force and improved LVEF [9] .
Clinical implications of our findings
In our patients, MR progression was seen in 69 (16%) of all patients undergoing CABG. We recommend preoperative and post-CABG echocardiogram in patients with risk factors for MR including presence of PDA lesion. Also, our study gives insights into how MR may be prevented post-CABG. Initially, aggressive revascularization strategy should be encouraged; especially, in patients with risk factors for MR development, PDA disease, hibernating myocardium or 2+ MR. Secondly, as development of 3-4+ MR is very common in those with 2+ MR, strong consideration should be given to mitral valve repair concomitantly with CABG in these patients. Thirdly, beta-blocker therapy use should be strongly encouraged in these patients. Lastly, in patients with LBBB (with poor LV function), CRT may potentially prevent MR progression. However, our study was not designed to address this issue.
Study limitations
This is a retrospective observational study, hence has its inherited limitations. Also this study has a small number of patients because pre-CABG and post-CABG echocardiograms were not done in all patients undergoing CABG. Performance of a postoperative echocardiogram may have been triggered by some symptoms or signs and may introduce a selection bias and potentially lead to overestimation of postoperative MR occurrence. Only, prospective data collection with systematic echocardiographic follow-up in all may eliminate this bias. We have no specific viability study to relate pre-CABG and post-CABG wall motion abnormalities. The quantitative details of medical therapy before and after surgery are not available. Despite of these limitations, the findings of this study give insights into predictors of MR progression and potential strategies to prevent its occurrence, in those patients undergoing CABG alone.
Editorial comment
Mild-moderate ischemic mitral regurgitation:
should it be treated together with CABG?
In a paper published in this issue of the Journal, Campwala et al. [1] review their patients who were subjected to coronary artery bypass surgery (CABG), looking for incidence, predictors and mechanisms of progression of pre-existing or de novo mitral regurgitation (MR). They found that the development of significant MR following isolated CABG is common (16% of their cases). Progression from mild (2+) to moderate or severe MR was observed in one quarter of the patients. Female gender, history of renal insufficiency, lack of beta-blocker use, MR grade and presence of left bundle branch block were found to be independent predictors of MR progression.
The authors attempted to discuss the pathogenesis of mitral regurgitation and hypothesise that it may occur especially in patients with inadequate revascularization, especially in the area of the posterior descending artery, and in patients with 'natural progression of LV remodelling'. They believe that MR post-CABG may be prevented by an aggressive revascularization strategy, especially in patients with disease of the posterior descending artery, hibernating myocardium or 2+ mitral regurgitation and other risk factors for development of MR. They recommend 'strong consideration' of mitral valve repair concomitantly with CABG in patients with mild (2+) MR, as development of moderate to severe (3 to 4+) MR is very common in these cases. This is an interesting observational study. To my knowledge, it is the first to analyse risk factors for progression of minimal or mild MR in patients undergoing CABG. It has some limitations, which the authors are the first to recognise, especially the fact that it is a retrospective observational study, including a relatively low number of patients studied and consequently, relatively few patients experiencing deterioration of the MR, and the fact that only patients who had preoperative and postoperative echocardiograms were studied. Nonetheless, I believe that these findings could be important to our comprehension of the problem of ischemic mitral regurgitation (IMR) and its treatment.
Chronic ('functional') IMR results from LV remodelling, which is translated by enlargement and dysfunction. In turn, it causes further ventricular and atrial enlargement and annular dilatation, thus creating a vicious circle that may not be reversed by correction of the myocardial ischemia alone. Tethering of the leaflets, especially the posterior, may occur due to abnormal motion of the LV wall. Evidently, IMR is not a disease of the mitral valve but of the LV; it is a dynamic dysfunction, caused by one or more of the above referred mechanisms and must be treated if severe (grade 3/4+). There is a distinction between the dysfunction caused by previous infarction and that caused by active (presumably reversible) ischemia. We should not ignore the dysfunction resulting from viable hibernating but recoverable myocardium [2] .
IMR occurs in about 10% of coronary bypass operations and is moderate or severe in 4%. It is usually associated to right coronary or circumflex artery disease (posterior papillary muscle), with restricted posterior leaflet motion. Annular dilatation occurs in 100% of cases and is its sole cause in more than half. Hence, most often repair is easy: just an annuloplasty (ring or suture). Valve replacement is rarely required or justified in chronic cases.
Mitral valve repair is now very widely practiced by most surgical groups and, in the hands of the most experienced, feasible in 85-90% of the cases in most types of pathology, including ischemic. In my own experience, it was possible in 93% of all patients with IMR, defined as MR secondary to ischemia or acute myocardial infarction and no history of rheumatic, degenerative or congenital valve disease, treated concomitantly with coronary revascularization.
In 1997, Perier et al. (personal communication) reported the first large series of mitral valve repair in 187 patients with severe IMR. Early mortality was 4.8% and 5-year survival was 54 AE 14% (60 AE 14% in patients with EF > 45%). Freedom from reoperation was 95 AE 4%. These results proved that not only the procedure is feasible with low mortality and morbidity but also it leads to very favourable medium and long-term results, by comparison with the natural history of the disease.
